Drug Approval Summaries: Arsenic Trioxide, Tamoxifen Citrate, Anastrazole, Paclitaxel, Bexarotene
Martin H. Cohen(United States Food and Drug Administration), Richard Pazdur(United States Food and Drug Administration), Susan Flamm Honig(United States Food and Drug Administration), Amna Ibrahim(Beni-Suef University), James J. O’Leary(United States Food and Drug Administration), Grant A. Williams(United States Food and Drug Administration), Robert M. White(National Institutes of Health), John R. Johnson(Santa Barbara Museum of Natural History), Steven Hirschfeld(United States Food and Drug Administration)
Cited by 102
Related Papers
Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis
|The Lancet|2014|4.7k
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
|The Oncologist|2007|1.4k
FDA Approval Summary: Pembrolizumab for the Treatment of Microsatellite Instability-High Solid Tumors
|Clinical Cancer Research|2019|1.2k